
    
      The investigators would like to see if women at increased risk for breast cancer are likely
      to tolerate SDG daily for 12 months without significant side effects or changes in their
      menstrual cycles. The investigators would also like to determine if BrevailÂ® can reduce
      breast cell proliferation in pre-menopausal women.
    
  